PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
47.13%
Some net income increase while CRVO is negative at -6.87%. John Neff would see a short-term edge over the struggling competitor.
3.87%
Less D&A growth vs. CRVO's 16.28%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
17.23%
Deferred tax of 17.23% while CRVO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-49.98%
Negative yoy SBC while CRVO is 3.43%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
93.54%
Well above CRVO's 43.86% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
48.23%
AP growth well above CRVO's 39.43%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
21.18%
Lower 'other working capital' growth vs. CRVO's 69.29%. David Dodd would see fewer unexpected short-term demands on cash.
-49.98%
Negative yoy while CRVO is 97.09%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
33.57%
Operating cash flow growth above 1.5x CRVO's 1.71%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-2609.70%
Negative yoy CapEx while CRVO is 69.18%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2609.70%
We reduce yoy invests while CRVO stands at 69.18%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
5.36%
Debt repayment growth of 5.36% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-80.40%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.